Just a reminder,We are waiting on the (overdue) results from...

Just a reminder,

We are waiting on the (overdue) results from NCT03522298, the Kazia sponsored Glioblastoma trial.

IMHO, this is a potentially huge pivotal moment for the company and patients given the:

• Positive results reported more than once previously (improvement on SoC);
• Consistency of the results so far;
• Lack of progress in GB treatments in recent decades;
• Paucity of options available to patients.

No news in cancer trials is sometimes good news (possibly patients continuing on treatment and no reportable adverse events).

If the results are similar to those reported in Nov last year, what kind of licensing deal could we see?

Be great to see a deal done on the back of the kaizia sponsored trial, amongst the plethora of invited trials.

GLTA.